5 research outputs found
Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours
BACKGROUND: Malignant mixed Mullerian tumours (MMMTs) of the uterus and
adnexa represent aggressive gynaecologic malignancies with a high rate
of loco-regional and distant failure. For that reason, we evaluated the
paclitaxel-ifosfamide-carboplatin (TICb) combination in patients with
advanced MMMTs.
METHODS: Female patients with advanced MMMTs, WHO-PS 0-2, no prior
chemotherapy for systemic disease, unimpaired haemopoietic and organ
function were eligible. Chemotherapy was administered at the following
doses; paclitaxel: 175 mg m(-2) on day 1, ifosfamide: 2.0 g m(-2)
day(-1) - days 1 and 2, and carboplatin at a target area under the curve
5 on day 2, with prophylactic G-CSF from day 3.
RESULTS: Forty patients of a median age 61 (45-72) years, performance
status 0-2 with advanced MMMTs of the uterus (n = 34), tubes (n = 2) or
ovary (n = 4) have entered and all were evaluable for response and
toxicity. Responses were as follows: 27 out of 40 (67.5%) evaluable
patients responded, with 11 complete responses and 16 partial responses,
while 10 had stable disease, and 3 developed progressive disease. The
median response duration was 9 months (range, 4-40 months), median
progression-free survival 13 months (range, 3-42 months), while median
overall survival 18 months (range, 4-48 months). Grade 3/4 neutropenia
was recorded in 22 out of 40 (55%) - with 13 developing grade 4 (<= 7
days) and 7 out of 40 (17.5%) of patients at least one episode of
febrile neutropenia.
CONCLUSION: In this study, it appears that the TICb combination, yielded
important activity with manageable toxicity in females with advanced
MMMTs warranting further randomised comparison with current standard
regimens. British Journal of Cancer (2011) 105, 897-902.
doi:10.1038/bjc.2011.316 www.bjcancer.com Published online 16 August
2011 (C) 2011 Cancer Research U
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
BACKGROUND: Recurrent or metastatic cervical cancer represents an
aggressive malignancy with a high rate of locoregional and distant
failure. Therefore, we evaluated the three-drug combination of
paclitaxel-ifosfamide-cisplatin ( TIP).
METHODS: Systemic chemotherapy-naive patients with advanced
metastatic/relapsed cervical cancer and a World Health Organization (
WHO) performance status ( PS) of 0-2 were eligible. TIP chemotherapy
doses were paclitaxel 175 mg m(-2) on day 1, ifosfamide 2.5 g m(-2) on
days 1 + 2, and cisplatin 40 mg m(-2) on days 1+2, with prophylactic
granulocyte-colony stimulating factor.
RESULTS: A total of 42 patients with recurrent/metastatic cervical
cancer are evaluable for response and toxicity: median age: 56 (25-74)
years; PS: 1 (0-2); histologies-squamous: 35, adenosquamous: 5, and
adenocarcinoma: 2. Responses were overall response rate (RR): 62% (95%
confidence interval (CI): 47.3-76.7%), with complete response (CR):
26% ( 95% CI: 12.7-39.3%), and partial response (PR): 36% ( 95% CI:
21.5-49.9%). Responses according to the relapse site were overall RR:
32% ( 95% CI: 13.7-50.3%) within previously irradiated pelvis vs 75%
(95% CI: 57.7-92.3%) in extra-pelvic sites. Median time to progression
(TTP) was 7 (range, 2-34+) months and median overall survival (OS) was
16.5 (range, 3-36+) months. Toxicities included grade 3-4 neutropenia:
83% (21% febrile neutropenia), grade 3-4 thrombocytopenia: 9%, no
grade 3 neuropathy (35% grade 2), grade 2 asthenia/fatigue 15%, and no
treatment-related deaths.
CONCLUSION: TIP is an active regimen with acceptable toxicity in
advanced/ relapsed cervical cancer. British Journal of Cancer ( 2009)
101, 1059-1065. doi:10.1038/sj.bjc.6605305 www.bjcancer.com Published
online 8 September 2009 (C) 2009 Cancer Research U